Response to Mittal and Sharma Letter to the Editor. Arthritis & rheumatology (Hoboken, N.J.) Spiera, R., Chung, L., Frech, T., Domsic, R., Hsu, V., Furst, D., Simms, R., Mayes, M., Martyanov, V., Whitfield, M., Dgetluck, N., Dinh, Q., White, B. 2020


On behalf of the authors, we appreciate the interest from Mittal and Sharma in the Phase 2 study results of lenabasum for the treatment of diffuse cutaneous systemic sclerosis (dcSSc) [1]. The small sample size and specified set of efficacy analyses done in this study preclude separate subset analyses of the course of interstitial lung disease, pulmonary artery hypertension, gastrointestinal involvement, or all efficacy analyses by disease duration or background immunosuppressant use, over 16 weeks.

View details for DOI 10.1002/art.41579

View details for PubMedID 33164325